AMCP Submits Comments to FDA on Biosimilars Labeling Draft Guidance Advocating for Changes to the Biosimilarity Statement and Biosimilar Product Identification & Naming Sections
AMCP Submits Comments to FDA on Biosimilars Labeling Draft Guidance Advocating for Changes to the Biosimilarity Statement and Biosimilar Product Identification & Naming Sections